- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02171533
Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers
Relative Bioavailability of Single Oral Doses of 150 mg Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages (240 mg and 480 mg Daily) (Open-label, Fixed-sequence Design), and Relative Bioavailability of Single Oral Doses of 150 mg Dabigatran Etexilate Given With or Without Single Oral Doses of 120 mg (IR) or 240 mg (ER) of Verapamil Administered at Different Time Points Relative to Dabigatran Etexilate Dosing in Healthy Male and Female Volunteers (Open-label, Randomised, Five-way Crossover Design, Phase I Study)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion criteria:
- Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests
- Age ≥18 and ≤55 years
- Body mass index (BMI) ≥18.5 and BMI ≤29.9 kg/m2
- Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation
Exclusion criteria:
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Relevant surgery of gastrointestinal tract
- History of any bleeding disorder or acute blood coagulation defect
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Pulse rate below 50 bpm and or systolic blood pressure <90 mm Hg at screening. ECG: PR >170 ms (Part 1), AV block ≥1st degree (Part 2) at screening
- Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within four weeks prior to administration or during the trial, especially intake of medication, which influences the blood clotting, i.e., acetylsalicylic acid, cumarin etc.
- Participation in another trial with an investigational drug within two months prior to administration or during the trial
- Smoker (more than 15 cigarettes or 3 cigars or 3 pipes per day)
- Alcohol abuse (more than 60 g/day for men and more than 40 g/day for women)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- Excessive physical activities (within one week prior to administration or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance
- Planned surgeries within four weeks following the end-of study examination
The subject is not able to understand and comply with protocol requirements, instructions, protocol-stated restrictions and dietary regimen of study centre
For male subjects:
Male subjects who do not agree to minimise the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the post study medical. Acceptable methods of contraception comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least two month)
For female subjects:
- Pregnancy / positive pregnancy test, or planning to become pregnant during the study or within 1 month of study completion
- No adequate contraception during the study and until 1 month of study completion, i.e. implants, injectables, combined oral contraceptives, IUD (intrauterine device), sexual abstinence (for at least 1 month prior to enrolment), vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (incl. hysterectomy). Females, who have not a vasectomised partner, are not sexually abstinent or surgically sterile will be asked to additionally use barrier contraception methods (e.g. condom, diaphragm with spermicide)
- Lactation period
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Fixed sequence
Treatments will be given in a fixed sequence
|
|
Sperimentale: Crossover
Treatments will be given in randomized sequences
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
AUC0-infinity (area under the concentration-time curve of total dabigatran over the time interval from 0 extrapolated to infinity)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
Cmax (maximum measured concentration of total dabigatran)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
AUC0-infinity (area under the concentration-time curve of free dabigatran over the time interval from 0 extrapolated to infinity)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
Cmax (maximum measured concentration of free dabigatran)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
AUC0-infinity (area under the concentration-time curve of verapamil over the time interval from 0 extrapolated to infinity)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
Cmax (maximum measured concentration of verapamil)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
AUC0-24 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 h after the administration)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
tmax (time from dosing to the maximum concentration of the analyte in plasma)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
λz (terminal rate constant in plasma)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
t1/2 (terminal half-life of the analyte in plasma)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
MRTpo (mean residence time of the analyte in the body after oral administration)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
CL/F (apparent clearance of the analyte in the plasma after extravascular administration)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
AUCτ,ss (area under the concentration-time curve of verapamil within the uniform dosing interval τ)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
AUC0-tz,ss (area under the concentration-time curve of verapamil from the time point 0 after the last dose at steady state to the last quantifiable analyte plasma concentration within the uniform dosing interval τ)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
Cmax,ss (maximum concentration of verapamil at steady state)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
tz,ss (time of last measureable concentration of verapamil within the dosing interval τ at steady state)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
tmax,ss (time from last dosing to the maximum concentration of verapamil at steady state on day 4)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
CL/F,ss (apparent clearance of verapamil at steady state after extravascular multiple dose administration)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
Cmin,ss (minimum measured concentration of verapamil at steady state over a uniform dosing interval τ)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
tmin,ss (time from last dosing to the minimum concentration of verapamil at steady state over a uniform dosing interval τ)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
Cpre,ss (predose concentration of verapamil at steady state immediately before administration of the next dose)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
Cavg (Average concentration of verapamil at steady state)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
MRTpo,ss (mean residence time of verapamil in the body at steady state after oral administration)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
Ae0-24 (amount of dabigatran that is eliminated in urine from the time interval 0-24h)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
fe0-24 (fraction of administered drug excreted unchanged in urine from time point 0- 24h)
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
CLR0-24 (renal clearance of dabigatran from the time point 0 until the time point 24h )
Lasso di tempo: up to 107 hours
|
up to 107 hours
|
|
AUEC0-24 (area under the effect curve)
Lasso di tempo: up to 107 hours
|
for ecarin clotting time and thrombin time
|
up to 107 hours
|
ERmax (maximum effect ratio)
Lasso di tempo: up to 107 hours
|
for ecarin clotting time and thrombin time
|
up to 107 hours
|
Occurence of Adverse Events
Lasso di tempo: within 5 days after last drug administration
|
within 5 days after last drug administration
|
|
Assessment of Tolerability by investigator
Lasso di tempo: within 5 days after last drug administration
|
within 5 days after last drug administration
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Agenti antiaritmici
- Agenti vasodilatatori
- Inibitori enzimatici
- Inibitori della proteasi
- Modulatori di trasporto a membrana
- Ormoni e agenti regolatori del calcio
- Antitrombine
- Inibitori della Serina Proteinasi
- Anticoagulanti
- Bloccanti dei canali del calcio
- Dabigatran
- Verapamil
Altri numeri di identificazione dello studio
- 1160.74
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Verapamil
-
Bristol-Myers SquibbCompletato
-
University of PittsburghNational Institute of Mental Health (NIMH)Completato
-
Medical University of GrazJuvenile Diabetes Research FoundationReclutamentoDiabete mellito, tipo 1Regno Unito, Belgio, Polonia, Austria, Francia, Germania, Italia
-
Benjamin BleierTerminato
-
University of AlbertaCompletato
-
AbbottCompletato
-
Shandong Suncadia Medicine Co., Ltd.CompletatoEffetto delle compresse di Verapamil sulla farmacocinetica delle compresse HRS-1893 in soggetti saniCardiomiopatia Ipertrofica OstruttivaCina
-
University Health Network, TorontoRitirato
-
Menzies School of Health ResearchAga Khan University; University of Melbourne; Universitas Sumatera Utara; Ethiopian... e altri collaboratoriReclutamentoVivax Malaria | Malaria, Vivax | Plasmodium Vivax | Ricaduta della malariaCambogia, Etiopia, Indonesia, Pakistan
-
Center Laboratories, Inc.TerminatoCefalea a grappolo episodicaRegno Unito